ATAI Life Sciences Files 8-K Report

TL;DR

ATAI Life Sciences filed an 8-K on 10/10/25, expect updates on financials/events.

AI Summary

On October 10, 2025, ATAI Life Sciences N.V. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and operational events. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing signals to investors and the market that ATAI Life Sciences is providing updated information, potentially impacting their understanding of the company's current standing and future outlook.

Risk Assessment

Risk Level: low — The filing is a routine disclosure (8-K) without immediate negative or positive news, thus carrying a low inherent risk.

Key Players & Entities

• ATAI Life Sciences N.V. (company) — Registrant
• October 10, 2025 (date) — Date of report

FAQ

Filing Documents

• ef20056757_8k.htm (8-K) — 35KB
• ef20056757_ex99-1.htm (EX-99.1) — 538KB
• 0001140361-25-037941.txt ( ) — 737KB
• atai-20251010.xsd (EX-101.SCH) — 4KB
• atai-20251010_lab.xml (EX-101.LAB) — 22KB
• atai-20251010_pre.xml (EX-101.PRE) — 16KB
• ef20056757_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. This Current Report on Form 8-K is being filed to provide additional information related to Beckley Psytech Limited, a company incorporated in England and Wales ("Beckley Psytech"), in connection with the previously announced share purchase agreement, dated June 2, 2025 (the "SPA"), by and among ATAI Life Sciences N.V., a Dutch public company with limited liability ("atai" or the "Company"), Beckley Psytech and certain other parties thereto, pursuant to which atai agreed to acquire from the shareholders of Beckley Psytech, excluding atai, the entire issued share capital of Beckley Psytech not already owned by atai (the "Transaction"). The unaudited interim condensed consolidated financial statements of Beckley Psytech Limited as of June 30, 2025 and for the six months ended June 30, 2025 and 2024 are attached hereto as Exhibit 99.1 and incorporated herein by reference. The Transaction is currently expected to close in the fourth quarter of 2025, subject to approval by atai's shareholders and satisfaction of other customary closing conditions. No assurance can be given that the Transaction will be consummated within this timeframe or at all. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "anticipate," "initiate," "could," "would," "project," "plan," "potentially," "preliminary," "likely," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements i

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Unaudited interim condensed consolidated financial statements of Beckley Psytech Limited as of June 30, 2025 and for the six months ended June 30, 2025 and 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: October 10, 2025 By: /s/ Srinivas Rao Name: Srinivas Rao Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR